MedKoo Cat#: 464515 | Name: BIIL315

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BIIL 315 is a highly potent LTB4 receptor antagonist with high affinity (Ki = 1.9 nM). Therefore, BIIL315 is a perfect tool compound to study LTB4 antagonism in vitro. The molecule is derived from prodrug BIIL 284. BIIL 284 itself displays negligible binding affinity (Ki = 230 nM), but is suitable for in vivo applications where it is metabolized into the active metabolite BIIL 315 upon p.o. administration.

Chemical Structure

BIIL315
BIIL315
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 464515

Name: BIIL315

CAS#: unknown

Chemical Formula: C36H38N2O9

Exact Mass: 642.2577

Molecular Weight: 642.71

Elemental Analysis: C, 67.28; H, 5.96; N, 4.36; O, 22.40

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BIIL315; BIIL 315; BIIL-315;
IUPAC/Chemical Name
(2S,3S,4S,5R,6S)-6-(4-(2-(4-((3-((4-carbamimidoylphenoxy)methyl)benzyl)oxy)phenyl)propan-2-yl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
InChi Key
FIMQVXNJBFDOAA-RSENBJTISA-N
InChi Code
InChI=1S/C36H38N2O9/c1-36(2,25-10-16-28(17-11-25)46-35-31(41)29(39)30(40)32(47-35)34(42)43)24-8-14-27(15-9-24)45-20-22-5-3-4-21(18-22)19-44-26-12-6-23(7-13-26)33(37)38/h3-18,29-32,35,39-41H,19-20H2,1-2H3,(H3,37,38)(H,42,43)/t29-,30-,31+,32-,35+/m0/s1
SMILES Code
O[C@H]1[C@H](O)[C@@H](O)[C@H](OC2=CC=C(C(C)(C)C3=CC=C(OCC4=CC=CC(COC5=CC=C(C(N)=N)C=C5)=C4)C=C3)C=C2)O[C@@H]1C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 642.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Alten R, Gromnica-Ihle E, Pohl C, Emmerich J, Steffgen J, Roscher R, Sigmund R, Schmolke B, Steinmann G. Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis. 2004 Feb;63(2):170-6. doi: 10.1136/ard.2002.004499. PMID: 14722206; PMCID: PMC1754875. 2: Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax. 2002 Aug;57(8):709-14. doi: 10.1136/thorax.57.8.709. PMID: 12149532; PMCID: PMC1746407. 3: Birke FW, Meade CJ, Anderskewitz R, Speck GA, Jennewein HM. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66. PMID: 11259574.